Objective To investigate the effect of increase extent of serum CA19-9 and CA125 in predicting resectability of pancreatic ductal adenocarcinoma preoperatively. Methods From January 2009 to December 2015, the clinical data of 441 patients with pancreatic ductal adenocarcinoma who were diagnosed pathologically and were evaluated to be resectable by radiology in our hospital were retrospectively analyzed. Patients were divided into resectable group and non-resectable group according to R0 resection. Preoperative serologic tumor markers including CA 19-9 and CA 125 in 2 groups were analyzed. Results There was significant statistical difference in CA19-9 and CA125 between resectable group and non-resectable group (P< 0.001). After correction of CA19-9 in the patients with direct bilirubin higher than 34.2 μmol/L, significant statistical difference in CA19-9 between two groups was still present (P< 0.001). Logistics multiple regression analysis and ROC curve showed that CA19-9 (cut-off= 582.10 U /mL, and adjusted CA19-9 cut-off= 449.70 U/mL) and CA125 (cut-off= 41.45 U/mL) were selected as predicting markers in resectability of pancreatic ductal adenocarcinoma. Conclusions Preoperative increase extent of CA19-9 and CA125 could assist to predict resectability of pancreatic ductal adenocarcinoma. The patients will have no chance of R0 resection when tumor markers increase more than cut-off value.
LI Fanlu, WU Zhichong, ZHAN Qian, SHEN Baiyong
. Validation of CA19-9, CA125in predicting respectability of pancreatic ductal adenocarcinoma[J]. Journal of Surgery Concepts & Practice, 2019
, 24(02)
: 163
-167
.
DOI: 10.16139/j.1007-9610.2019.02.016
[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[3] Dumitra S, Jamal MH, Aboukhalil J, et al.Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score[J]. HPB (Oxford),2013,15(12):1002-1009.
[4] 李宁, 沈世强, 刘建超. 血清CA19-9, CA242, CEA及CA125在胰腺癌诊断和预后中的价值[J]. 中国普外基础与临床杂志,2011,18(3):300-304.
[5] Chen T, Zhang MG, Xu HX, et al.Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma[J]. Medicine (Baltimore),2015,94(19):e751.
[6] Liu L, Xu HX, Wang WQ, et al.Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden[J]. Oncotarget,2016,7(5):5943-5956.
[7] 白燕南, 严茂林. 胰腺癌综合诊治指南(2018版)外科相关部分解读[J]. 中国普外基础与临床杂志,2018,25(6):669-672.
[8] Hirano K, Kawa S, Oguchi H, et al.Loss of lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels[J]. J Natl Cancer Inst,1987, 79(6):1261-1268.
[9] Kang CM, Kim JY, Choi GH, et al.The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer[J]. J Surg Res,2007,140(1):31-35.
[10] Humphris JL, Chang DK, Johns AL, et al.The prognostic and predictive value of serum CA19.9 in pancreatic cancer[J]. Ann Oncol,2012,23(7):1713-1722.
[11] Chan A, Prassas I, Dimitromanolakis A, et al.Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer[J]. Clin Cancer Res,2014,20(22):5787-5795.
[12] 吴文辉, 肖隆斌, 杨世斌, 等. 监测血清肿瘤标志物水平预测结肠癌根治术后复发或转移的意义[J]. 消化肿瘤杂志(电子版),2010,2(2):93-96.
[13] Yang C, Cheng H, Luo G, et al.The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system[J]. Eur J Surg Oncol,2017,43(11):2112-2118.
[14] Ni XG, Bai XF, Mao YL, et al.The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer[J]. Eur J Surg Oncol,2005, 31(2):164-169.
[15] Im HJ, Oo S, Jung W, et al.Prognostic value of metabo-lic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer[J]. Medicine (Baltimore),2016,95(19):e3686.
